TABLE 2.
Comparison of 12 glycoform ratios of plasma IgA1 HR in the participants.
| Glycoform Ratio | IgAN (n = 62) | DC (n = 30) | HC (n = 30) | p value |
|---|---|---|---|---|
| GalNAc3Gal1, median (IQR) | 0.38% (0.18–1.31%) | 0.70% (0.09–2.71%) | 0.36% (0.11–1.26%) | 0.542 |
| GalNAc3Gal2, median (IQR) | 1.49% (0.81–2.09%) | 1.18% (0.63–1.90%) | 1.18% (0.85–1.39%) | 0.144 |
| GalNAc3Gal3, median (IQR) | 7.52% (5.30–10.00%) | 4.00% (2.76–5.30%)a | 4.39% (3.08–5.50%)b | <0.001 |
| GalNAc4Gal2, median (IQR) | 1.96% (1.00–2.76%) | 1.67% (1.08–2.92%) | 0.98% (0.69–1.72%)b | 0.005 |
| GalNAc4Gal3, mean ± SD | 15.86 ± 4.62% | 14.08 ± 5.27% | 15.11 ± 3.11% | 0.206 |
| GalNAc4Gal4, mean ± SD | 28.85 ± 7.06% | 29.35 ± 8.35% | 29.02 ± 6.46% | 0.953 |
| GalNAc5Gal3, median (IQR) | 6.83% (4.36–11.31%) | 5.94% (4.23–8.53%) | 6.31 (4.71–10.08%) | 0.631 |
| GalNAc5Gal4, mean ± SD | 27.36 ± 6.02% | 34.31% ± 7.37%a | 28.43 ± 5.17% | <0.001 |
| GalNAc5Gal5, median (IQR) | 4.15% (2.91–6.38%) | 5.41% (3.57–7.27%) | 6.47% (5.26–9.20%)b | <0.001 |
| GalNAc6Gal3, median (IQR) | 1.03% (0.65–1.96%) | 1.37% (0.58–2.71%) | 1.34% (0.88–2.53%) | 0.111 |
| GalNAc6Gal4, median (IQR) | 1.13% (0.75–2.11%) | 1.75% (0.86–2.97%) | 1.90% (1.48–2.29%)b | 0.014 |
| GalNAc6Gal5, median (IQR) | 0.73% (0.43–1.00%) | 1.28% (0.66–2.41%)a | 0.90% (0.60–1.91%) | 0.006 |
Abbreviation: IQR: interquartile range. The p value represents the statistical difference in the relative abundance of glycoforms among the three groups. pa < 0.05: IgAN, vs. DC; p b < 0.05: IgAN, vs. HC.